Manufacturing improvements over the past 90 years have resulted in safer and more convenient forms of insulin for patients with diabetes mellitus. 3, 5 However, improvements in insulin formulations have come with increased costs. [6] [7] [8] [9] [10] [11] In recent years, studies have demonstrated a shift in use from older forms of insulin (eg, human insulin) to newer, more expensive analogs. 4, 12 A recent article traced the historical evolution of insulin from animal to human to synthetic analogs. 5 Although the comparative evidence of clinical benefit for newer insulins is limited, with a few studies suggesting reduced rates of nocturnal hypoglycemia or improved adherence, [13] [14] [15] newer analogs are generally more expensive than older insulin formulations. 12 These changes in the insulin market contributed to an increase in outof-pocket expenditures for those with private health insurance. 12 High costs also strain the budgets of government payors such as Medicaid. 16, 17 One contributor to the high cost of insulin is the lack of competition. Currently, 3 manufacturers (Eli Lilly, Sanofi Aventis, and Novo Nordisk) account for more than 90% of the global insulin market. 18, 19 They also produce the entire insulin supply for approximately 3 million adult diabetic patients in the United States. 20 For these reasons, the US insulin market behaves differently from the trend in pharmaceutical markets where generic competition results in substantial price reductions after patent expiration. 21 Although generic insulins may become available to patients in the United States in the next several years (glargine [Abasaglar; Lilly/Boehringer Ingelheim] has been available in Europe since September 2014), there are currently no generic manufacturers that produce insulin for the US market. We examined trends in Medicaid payments for currently available insulin products in the United States from 1991 to 2014. We chose Medicaid because cost information is available for all 50 states and the District of Columbia and has been recorded consistently since the start of the Medicaid Drug Rebate Program in 1990. Additionally, Medicaid programs are sensitive to changes in costs and cover a high-risk patient population with little capacity to absorb additional costs of medications themselves.
Methods
Using the US Food and Drug Administration's (FDA) National Drug Code (NDC) Directory, we obtained a list of all commercial insulin products marketed to patients in the United States in December 2014. We used the Drug Topics Red Book to identify a subsample of insulin products that were both recently available and continuously marketed and then crossreferenced this list with what was available in 2006 when the Medicare Part D prescription drug benefit that also affected the number of patients receiving pharmacy benefits from Medicaid was started. 22 We excluded NDCs from discontinued products and repackagers. We also excluded regular human insulin, U-500 (concentrated) (Humulin R U-500; Eli Lilly and Company) due to its atypical dosage strength. Humulin R U-500 is different from all other insulin products because it contains 500 IU per 1 mL of solution; other insulin products typically contain 100 IU per 1 mL. The remaining 16 products were classified into rapid-acting and long-acting analogs, shortacting, intermediate, and premixed insulins based on American Diabetes Association Guidelines ( Table 1) . We obtained quarterly data on reimbursements and the number of units procured for each of these insulin products from the Medicaid State Drug Utilization Database. We excluded data from the third quarter of 2001 to the fourth quarter of 2002 for aspart (Novolog; Novo Nordisk) vials in Minnesota and excluded the first quarter of 2012 to the second quarter of 2012 for NPH (Novolin N; Novo Nordisk) vials in Hawaii because they were extreme outliers. In these cases, the amount reimbursed per unit was approximately 20-fold higher than the national mean. We aggregated the remaining statelevel data to form national totals and examined data from the first quarter of 1991 to the second quarter of 2014. We standardized payments per NDC unit by dividing total Medicaid reimbursements in US dollars by the total number of units procured for each quarter. To account for different formulations, we report reimbursements per NDC unit, with each unit representing 1 mL (100 IU) of standard-strength insulin.
We adjusted for inflation using annual Consumer Price Indexes and report all values in 2014 US dollars. For the primary time-series analysis, we plotted reimbursements per NDC unit of insulin against calendar time in quarters. We used the line chart option in Excel 2007 (Microsoft Corporation) to generate cost figures. This charting option is a standard way of summarizing data recorded over time and connects plotted values using simple lines. No curve fitting or regression techniques were used. Total reimbursements include dispensing fees but exclude manufacturer rebates or rebates from supplemental rebate agreements, which are confidential agreements between drug manufacturers and states that allow additional rebates beyond what is mandated by the Centers for Medicare and Medicaid Services.
To place insulin costs in a clinical context, we compared average quarterly Medicaid reimbursements for a typical patient with diabetes and assumed daily use of 40 IU of insulin per day (0.4 NDC units) based on the standard established by the World Health Organization Anatomical Therapeutic Chemical (ATC) classification system guidelines for the defined daily dose of basal insulin. 24 Assuming use of only 1 insulin product at a time and no wasted insulin, the typical diabetic in our study would require 14 400 IU (40 IU/d × 30 d/mo × 12 mo/y) of insulin per year. We report annual costs to Medicaid at 3 time points: 1991 (start of database), 2001 (market introduction of glargine), and 2014 (end of database). We chose 2001 as a relevant time point because it represented 10 years after the start of our study period, and it marked the year of introduction of glargine (Lantus; Sanofi-Aventis), the top-selling insulin prod-uct in the United States. In 2014, there were more than 19.7 million prescriptions for this long-acting insulin analog.
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To compare rate of increase in reimbursements of patented with nonpatent-protected insulins, we used generalized linear models (PROC GLM) and an interaction term between year and patent status. A product was considered patented if there was a nonexpired patent in the FDA list of approved drug products with therapeutic equivalence evaluations (Orange Book) as of January 2013. 23 All computing was performed using SAS 9.4 (SAS Institute) or Excel 2007 (Microsoft Corporation).
Results
Since 1991, quarterly Medicaid reimbursements for insulin products on a per-unit basis have steadily increased (Figure 1 ). Medicaid reimbursements for rapid-acting insulin analogs have increased from $3.69 per unit when this class of insulins first appeared on the US market to $19.81 per unit in 2014. Long-acting insulins have historically been reimbursed at lower rates than rapid-acting analogs; however, a steep rise in payments during 2012 to 2014 for long-acting insulins has resulted in near-parity in reimbursements between these 2 categories ($19.78 for long-acting insulins vs $19.81 for rapidacting analogs in the second quarter of 2014). The rate of increase of reimbursements was higher for patented insulin products (ie, insulin analogs) than for nonpatent-protected insulins (ie, human insulin) (P < .001, Figure 2 ). When glargine was first introduced in 2001, patent-protected insulins were reimbursed on average at a rate that was 76% higher than the rate for nonpatent-protected insulins. By 2014, this rate had increased to 111%.
Total reimbursements by Medicaid for insulin increased from $10.7 million in the first quarter of 1991 to $178. Volume for insulin products rose in a manner similar to reimbursements: from 3.9 million units in the first quarter of 1991 to a peak of 29. For a patient with diabetes mellitus requiring 40 U of insulin per day, the annual inflation-adjusted cost to Medicaid for medication and dispensing fees was $370 for an average priced premixed insulin in 1991 and $2852 for an average priced rapid-acting insulin in 2014 ( Table 2) . Since the introduction of glargine in 2001, the annual cost to Medicaid for the same insulin products has increased from 284% for intermediateacting to 455% for premixed insulins.
When insulin pens were compared with insulin vials for the 16 insulin products in our study, the change in Medicaid reimbursements did not substantially differ (data not shown). 
Discussion
Between 1991 and 2014, we found a near-exponential upward trend in Medicaid payments for a wide variety of insulin products regardless of formulation, duration of action, and whether or not the product was patented. Although reimbursements for newer insulin analogs that are protected by patent are increasing at a faster rate than reimbursements for older insulins, quarterly payments increased for all products we examined. The choice of which insulin to start is clinical and based on a variety of factors. Some patients may require both basal and mealtime insulins to achieve adequate glycemic control. Other patients may prefer the convenience of prefilled pens or longer-duration analogs regardless of cost. As overall costs rise, state Medicaid programs are likely to increasingly use prescription management strategies to reduce drug spending. Such measures will disproportionately affect newer, more expensive insulin analogs. 26 Medicaid perscription management strategies may reduce therapeutic alternatives for patients and make it more difficult for physicians to prescribe certain regimens. From a policy perspective, our findings suggest that the insulin market in the United States lacks price competition. Some degree of competition might be expected owing to the diversity of insulin formulations available and the fact that 3 manufacturers control the market rather than just 1. The lack of insulin price competition follows a traditional pattern in the United States when a market for a particular drug product is controlled by a small number of brand-name manufacturers. Prior research has suggested that costs associated with insulin treatment are increasing because of the widespread adoption of insulin therapy and increasing use of newer, more expensive insulin analogs. 12 Others have suggested that rising insulin costs are related to incremental innovation by brandname manufacturers that has repeatedly precluded the development of a generic insulin industry in the United States. 5 Insulin manufacturers may be introducing gradual innovations in insulin formulations and delivery devices as a way to protect and extend their products' patent life, a practice called life cycle management or evergreening. 29 As some of these newer products age and approach the loss of their patent protection (or when a competing patented product enters the market), manufacturers may increase prices as a way to offset future revenue losses. Although some price increases may be warranted, such as when a new product provides clear benefits, the prices of older insulin formulations should drop or stay the same over time. Our analysis shows, however, that this has not been the case. Even after adjusting for inflation, prices and reimbursements for all insulin products have been increasing on a per-unit basis, regardless of their degree of innovation. A limitation of our study was that we could not determine net costs to states because manufacturer drug rebate amounts are confidential, as are state supplemental rebate agreements. It is unlikely, however, that rebates would offset the increases in payments that we identified because base Medicaid rebates for innovator drugs are the greater of 23.1% of the average manufacturer price (AMP) or the difference between AMP and the best price (the lowest price offered to any purchaser of that product, with a few exceptions, such as for drugs purchased by the Department of Veterans Affairs). 30 Another limitation was that we did not have data on state-by-state variation in prescription management strategies for insulin products (eg, formulary tier and cost-sharing) which can affect prescribing patterns, costs, and patient adherence. 31 Finally, our sample did not include reimbursement data from discontinued insulins or from any insulin products first marketed in the United States after 2006. Numerous policy options can be employed to combat rising insulin prices. If manufacturer rebates to Medicaid and other publicly funded insurance programs were transparent, net spending on these products would be known, which could help buyers negotiate more favorable purchasing contracts. Additionally, pricing standardization could decrease any stateto-state variability for medication purchases. Currently, there is wide variation in the formulas that states use to calculate reimbursements for drug ingredient costs. 32 Despite efforts to establish a single national pricing benchmark based on actual drug acquisition costs, many states continue to calculate ingredient costs based on published average wholesale prices or wholesale acquisition costs. 33, 34 These methods are not ideal because they reflect manufacturer suggested list prices rather than actual drug costs.
In addition, the FDA should clarify the steps needed to bring a generic version of insulin to the market, similar to the case in Europe. 35 An application for a formulation of glargine (Abasaglar; Eli Lilly and Boehringer Ingelheim) has been approved in Europe, but it remains unavailable in the United States owing partially to ongoing litigation. 36 Thus for the foreseeable future, insulin prices may continue to increase, notwithstanding that 6 of the 16 insulin products we studied have been off patent for many years and another 3 should soon be off patent (aspart, lispro, and glargine). By contrast, FDA analyses show that generic drug prices reach about 55% of the brandname price when 2 competitors are in the market, 33% when
